Cite
1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study.
MLA
Zhou, C., et al. “1031P Tislelizumab (TIS) versus Docetaxel (TAX) as Second- or Third-Line Therapy in Previously Treated Patients (Pts) with Locally Advanced Non-Small Cell Lung Cancer (NSCLC): Asian versus Non-Asian Subgroup Analysis of the RATIONALE-303 Study.” Annals of Oncology, vol. 33, Sept. 2022, pp. S1026–27. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.1157.
APA
Zhou, C., Huang, D., Fan, Y., Yu, X., Liu, Y., Shu, Y., Ma, Z., Wang, Z., Cheng, Y., Wang, J., Hu, S., Poddubskaya, E., Disel, U., Akopov, A., Dvorkin, M., Wang, Y., Ghassemifar, S., Li, S., & Rivalland, G. (2022). 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study. Annals of Oncology, 33, S1026–S1027. https://doi.org/10.1016/j.annonc.2022.07.1157
Chicago
Zhou, C., D. Huang, Y. Fan, X. Yu, Y. Liu, Y. Shu, Z. Ma, et al. 2022. “1031P Tislelizumab (TIS) versus Docetaxel (TAX) as Second- or Third-Line Therapy in Previously Treated Patients (Pts) with Locally Advanced Non-Small Cell Lung Cancer (NSCLC): Asian versus Non-Asian Subgroup Analysis of the RATIONALE-303 Study.” Annals of Oncology 33 (September): S1026–27. doi:10.1016/j.annonc.2022.07.1157.